当"双碳"目标的春风拂过广袤田野，农业绿色升级已成为不可逆转的时代潮流。然而，由于传统农业固 有的脆弱性与分散性，农业绿色转型技术门槛高、信用风险大、生态效益内化难，在绿色转型升级中面 临各类融资问题。对此，中国人民银行江津分行在中国人民银行重庆市分行的指导下，以转型金融为 媒，让银行放心大胆地助力企业可持续发展。 自重庆被确定为全国首批农业转型金融标准试用省市以来，中国人民银行江津分行迅速响应，紧扣农业 产业特点，联合多部门建立农业转型项目库，主动将符合条件的绿色项目纳入服务清单，变"企业找上 门"为"政策送上门"。同时，组建由行业主管部门、中国人民银行当地分支机构、金融机构和第三方评 估机构共同组成的"一对一服务团队"，从项目申报到贷款审批全程跟进，保障审批流程的顺畅和高效， 让企业少跑腿、贷款更便捷。 "以前贷款要看抵押物，现在看'碳足迹'就行？"广州双桥（重庆）股份有限公司财务负责人起初还有些 疑惑。这家专注淀粉糖生产的企业，想升级节能设备却苦于没有抵押物，是"碳足迹+信用"的融资模式 让他们吃下了"定心丸"。中国人民银行江津分行利用长江绿融通系统"碳账户"模块，为其淀粉糖产品核 算"碳账"，出具动态 ...

Group 1 - Shudao Equipment's subsidiary signed a construction contract worth 24.68 million yuan for a hydrogen fuel cell manufacturing base project [1] - Zhongliang Technology received a land acquisition compensation of 30 million yuan from the government [2] - Palm Holdings won a bid for a high-standard farmland construction project in Lankao County, with a contract value of 433 million yuan, accounting for 14.12% of the company's audited revenue for 2024 [3] Group 2 - Changchun Yidong's subsidiary received a government subsidy of 2.85 million yuan, which is 122.78% of the company's audited net profit for the last fiscal year [4] - Wuzhou Transportation successfully issued 200 million yuan in medium-term notes with an interest rate of 2.10% [5][6] - Tiandi Source's subsidiary plans to apply for a trust loan of up to 500 million yuan from related parties [8] Group 3 - Tiandi Source's subsidiary acquired a residential land use right in Xi'an for 2.015 billion yuan [9] - Opcon Vision received a medical device registration certificate for its ultrasonic nebulizer [11] - Jingjiawei announced the resignation of its vice president due to personal reasons [13] Group 4 - Fulinh Precision's subsidiary received a prepayment of 1.5 billion yuan from CATL for securing lithium iron phosphate material supply [15] - Yunzhu Technology's subsidiary received a government subsidy of 20.12 million yuan [16] - Kehua Bio's ferritin test kit received a medical device registration certificate [17] Group 5 - Jinghua Pharmaceutical's medical sodium alginate wound dressing received a medical device registration certificate [18] - Lingwei Technology established a wholly-owned subsidiary with a registered capital of 1 million yuan [19] - Sanwei Co. won a bid for concrete sleeper procurement projects worth 158 million yuan [20] Group 6 - Shanghai Pharmaceuticals' Nicardipine tablets passed the consistency evaluation for generic drugs [21] - Lushan New Materials increased its idle fund management limit to 750 million yuan [24] - Huayi Technology announced the retirement of a core technical staff member [25] Group 7 - Yingli Environment plans to use up to 300 million yuan of idle raised funds for cash management [30] - Yong'an Forestry plans to develop a national reserve forest project in Putian, Fujian, with an estimated investment of 154 million yuan [32] - Xinyuan Technology's shareholders plan to reduce their holdings by up to 3.18% of the company's shares [60]

Group 1: Company Overview and Market Position - COFCO Biotech is the only company approved to produce D-Alulose using specific enzymes in China, indicating a unique market position [1][2] - The company is actively expanding its D-Alulose market presence through self-built capacity and third-party collaborations [1][4] Group 2: Financial Performance and Stock Issuance - The non-public offering price is set at 9.38 CNY per share, while the current market price is 6.14 CNY, reflecting a significant discount [2][7] - The company aims to enhance shareholder value through strategic collaborations that exceed the capital value, compensating for the dilution of existing shareholders' equity [2][7] Group 3: Project Development and Future Plans - Current projects include a new starch sugar production facility with an annual capacity of 550,000 tons and a 30,000-ton lactide project, with ongoing expansions in Chengdu [2][7] - The D-Alulose project is expected to enter the food application market, with ongoing updates provided through regular reports and interactive platforms [1][4] Group 4: Regulatory and Market Environment - The company's strategy aligns with national policies promoting a unified market and reducing competition through technological upgrades rather than price competition [5][6] - The company has established a market value management system to enhance investment value and protect investor rights amid a significant market cap reduction of 5.9 billion CNY over seven years [7]

Core Points - The State Administration for Market Regulation (SAMR) is drafting regulations to standardize the bulk transportation of key liquid foods, aiming to enhance food safety through a licensing and management system [1][3][4] Group 1: Licensing and Management Regulations - A draft titled "Directory of Key Liquid Foods for Road Bulk Transportation Licensing System" has been released, proposing licensing management for key liquid food categories including edible vegetable oils, seasonings, alcoholic beverages, sugar, and starch sugars [3] - The proposed regulations will implement a licensing system for the transportation of specific liquid food varieties, detailing the types of food, transportation methods, and suitable containers for transportation [3] Group 2: Responsibilities and Risk Management - The "Management Measures for Road Bulk Transportation of Key Liquid Foods" draft outlines a responsibility framework for shippers, carriers, and receivers to ensure food safety throughout the transportation process [4] - The draft emphasizes the need for each party to fulfill their responsibilities and enhance supervision to mitigate risks associated with the transportation process [4] Group 3: Record Keeping and Information Management - The "Work Specification for Management of Liquid Food Road Bulk Transportation Waybills" draft mandates comprehensive record-keeping of food types, quantities, transportation information, seal status, and inspection results [5] - A standardized waybill must be filled out by all parties involved, ensuring thorough documentation of transportation information and cleanliness records [5]

Group 1: Industry Overview - The global trend towards "zero sugar" is reshaping consumer choices, with 75% of beverage consumers in China opting for sugar substitutes due to health concerns [1] - The global erythritol market is projected to reach approximately $910 million in 2024, with China dominating the market with a 73% share [1] - The rapid development of the sugar-reduction food industry is heavily reliant on biotechnology, particularly using corn as a raw material for natural sweeteners like erythritol [1] Group 2: Company Profile - Dongxiao Biotechnology Co., Ltd. is emerging as a significant player in China's biotechnology sector, leveraging advanced corn deep-processing technology and automated production capabilities [1] - The company has an annual corn processing capacity of 1.7 million tons, enabling a full-chain production process that includes the conversion of corn into erythritol, starch sugars, and amino acids [1] - Dongxiao has established partnerships with renowned brands such as Yuanqi Forest, Coca-Cola, Nestlé, Unilever, BASF, and Charoen Pokphand Group [2] Group 3: Technological Advancements - Dongxiao has a research team of nearly 200 members, including academicians and PhD holders, and has developed a four-tiered research and development system [2] - The company has optimized fermentation processes, reducing the fermentation cycle by 25% and increasing conversion rates by 5%, while also lowering energy consumption by 15% [2] - Dongxiao is preparing to launch the next generation of natural sweeteners, allulose, which has a sweetness level of about 70% compared to sucrose and only 10% of its calories [2] Group 4: Future Outlook - Dongxiao aims to continue expanding in the functional product sector and enhance the value chain of the health industry [3] - The company is positioned to contribute to the global health wave with its innovative approaches to "healthy sweetness" [3]

Core Insights - Erythritol, a key ingredient in the booming "zero-sugar" beverage market, is gaining attention, with Dongxiao Biological being a significant supplier for well-known companies like Yuanqi Forest [1] - Dongxiao Biological is planning to list on the New Third Board, having submitted its public transfer statement on June 30, with its application materials officially accepted [1] - The company, established in December 2004 and located in Zhucheng, Weifang City, focuses on synthetic biology manufacturing and fermentation technology, producing a range of products including animal nutrition, solid beverages, food additives, organic acids, and health sweeteners [1] Financial Performance - Dongxiao Biological's projected revenues for 2023 and 2024 are approximately 7.993 billion yuan and 7.840 billion yuan, respectively [1] - The net profits for the same periods are expected to be 298 million yuan and 578 million yuan [1] - The comprehensive gross profit margins are forecasted to be 10.33% and 13.91% for 2023 and 2024, respectively [1] Market Position - The global erythritol market is projected to reach approximately 910 million USD in 2024, with Chinese companies dominating the market with a 73% share, while Europe and the US combined account for about 22% [1] - Dongxiao Biological has established a complete value chain from raw materials to high-value products, utilizing its annual processing capacity of 1.7 million tons of corn [2] Production Efficiency - Dongxiao Biological has achieved significant breakthroughs in microbial fermentation, reducing the fermentation cycle by 25% and increasing the conversion rate by 5% compared to the industry average [3] - The company's erythritol products are supplied to major brands such as Yuanqi Forest, Coca-Cola, and Nestlé, contributing to the popularization of "zero-sugar" products [3] Future Developments - Dongxiao Biological is also focusing on the next generation of natural sweeteners, such as allulose, with a dedicated R&D team of nearly 200 members, including 5 PhDs and over 40 master's degree holders [3] - The company has established technology platforms for gene editing, high-throughput screening, and fermentation process regulation to drive innovation in biological manufacturing [3]

Core Insights - The global health food revolution is significantly linked to corn, with a rising demand for sugar alternatives driven by health consciousness and weight management needs [1] - The global erythritol market is projected to reach approximately $910 million in 2024, with China dominating the market with a 73% share [1] - Dongxiao Biotechnology Co., Ltd. is emerging as a key player in China's biotechnology sector, leveraging advanced corn deep processing technology and automation [1] Company Overview - Dongxiao Biotechnology operates a fully integrated value chain, converting corn into high-value products such as starch sugars, erythritol, and amino acids through precise fermentation and extraction processes [2] - The company has an annual corn processing capacity of 1.7 million tons, enabling it to produce a wide range of products, enhancing resource utilization efficiency and establishing a circular economy [2] Product Advantages - Erythritol is favored by many well-known brands due to its natural and safe profile, being the only natural sweetener recognized as having no daily intake limit by health authorities [3] - The safety of erythritol has been validated by organizations such as WHO and FDA, making it widely applicable in food, health products, cosmetics, and pharmaceuticals [3] Technological Innovation - Dongxiao Biotechnology has invested in a robust R&D team of nearly 200 members, focusing on synthetic biology and fermentation technology to enhance production efficiency [4][5] - The company has achieved a 25% reduction in fermentation cycle time and a 15% decrease in energy consumption through proprietary technologies, promoting green manufacturing practices [5] Future Developments - The company is strategically positioning itself in the next generation of natural sweeteners, specifically allulose, which has a sweetness level similar to sucrose but with significantly lower calories [6] - Dongxiao Biotechnology aims to expand its functional product offerings, including probiotics, functional amino acids, rare functional sugars, and biodegradable materials, to enhance the health industry value chain [6]

Core Insights - The global consumer trend towards reducing sugar intake is driven by increased health awareness and weight management needs, with 75% of beverage consumers in China opting for sugar substitutes [1] - The global erythritol market is projected to reach approximately $910 million in 2024, with China dominating the market with a 73% share [1][3] - Shandong Dongxiao Biotechnology Co., Ltd. is emerging as a key player in the biotechnology sector in China, leveraging advanced corn processing technology and automation [1][3] Industry Overview - The shift towards "sugar reduction" in the food industry is supported by biotechnology, with natural sweeteners like erythritol redefining "healthy sweetness" [1] - Erythritol is recognized for its natural and safe properties, being the only natural sweetener with no daily intake limit recognized by international authorities [5][6] - The company has established partnerships with major brands such as Yuanqi Forest, Coca-Cola, Nestlé, and Unilever, highlighting its strong market position [6] Company Operations - Dongxiao Biotechnology utilizes a complete value chain from raw material to high-value products, processing corn into various products including starch sugars and amino acids [3] - The company has a robust R&D team of nearly 200 members, focusing on continuous innovation and optimization of fermentation processes to enhance production efficiency [7] - The company has achieved significant improvements in production, including a 5% increase in conversion rate and a 30% reduction in energy consumption through advanced membrane technology [7] Future Developments - Dongxiao Biotechnology is positioning itself for the next generation of natural sweeteners, specifically allulose, which has a sweetness level similar to sucrose but only 10% of its calories [9] - The company aims to expand its product offerings in functional products, including prebiotics, functional amino acids, rare functional sugars, and biodegradable materials [9] - The ongoing innovation in research, manufacturing, and supply chain integration reflects the company's commitment to contributing to the global health trend [9]

Financial Performance - In the first half of 2025, the company achieved total revenue of 139,923.89 million yuan, a year-on-year increase of 18.02% [3] - The net profit attributable to shareholders, after deducting share-based payment expenses, was 9,532.72 million yuan, with a year-on-year growth of 32.15% [3] - The second quarter of 2025 saw revenue of 71,444.25 million yuan, a year-on-year increase of 12.63% and a quarter-on-quarter growth of 4.33% [3] Product Performance - The three core products (prebiotics, dietary fiber, and sugar-reducing sweeteners) generated revenue of 66,354.78 million yuan, a year-on-year increase of 32.15% [3] - Sugar-reducing sweeteners achieved revenue of 37,152.41 million yuan, growing by 61.22% [3] - Prebiotics generated revenue of 18,867.03 million yuan, with a year-on-year growth of 20.23% [3] - The revenue share of the three core products accounted for 47.42% of total revenue, an increase of 5.07% compared to the previous year [3] Cost Management - The overall gross margin for the first half of 2025 improved to 13.17%, up by 1.36% from the previous year [3] - The gross margin for the three core products was 17.94%, an increase of 1.93% year-on-year [3] - The company implemented cost control measures, including optimizing production processes and enhancing supply chain management to mitigate rising raw material costs [4] Business Development - In 2024, the company established projects for the annual production of 2,000 tons of DHA algae oil and 2,500 tons of HMOs (human milk oligosaccharides), which are expected to commence production in the second half of 2025 [5] - The company received approval for its HMO application as a new food nutrition fortifier in July 2025 [5] - The company is actively pursuing new product development in the field of synthetic biology, with several patents and trademarks registered in the first half of 2025 [6] Market Trends - The company noted that corn prices have been fluctuating, impacting production costs and gross margins [8] - The company’s products are primarily used in beverages, dairy products, functional foods, and health products, which typically do not exhibit significant seasonality [8] Strategic Initiatives - The establishment of a subsidiary in the United States is part of the company's strategy to enhance international business operations [9] - The company is focusing on expanding its market presence and product offerings in the field of synthetic biology and prebiotics [7]

Core Viewpoint - COFCO Biotech reported a significant increase in net profit for the first half of 2025, achieving a net profit attributable to shareholders of 107 million, a year-on-year increase of 74.4% [1]. Financial Performance - The company achieved a net profit of 107 million, up 74.4% year-on-year, and a non-recurring net profit of 31.9 million, up 71.5% [1]. - Despite stable production rates and overall sales, sales revenue decreased due to falling product prices, although gross margins for key products improved [1]. - The overall gross margin increased by 1.3 percentage points year-on-year, approaching 8.5%, with specific product contributions noted [2]. Business Strategies - The company implemented several cost-reduction measures, including enhancing procurement and sales integration, optimizing inventory management, and adopting a "slow procurement, fast sales" strategy [1]. - The company is focusing on new product sales, such as flavored syrups and modified starches, to improve overall gross margins [1]. - The enzyme-based production of allulose has received approval from the health authority, providing a first-mover advantage in the domestic market [1]. Business Segment Insights - Fuel ethanol business remains stable with a market demand of 3-3.5 million tons, and the company maintains a high market share [2]. - The starch sugar business is expanding, with a 150,000-ton expansion project nearing completion and expected to start production by the end of September [2]. - The allulose product is positioned as a key growth area, with significant investment in enzyme research and development, and is expected to see increased demand in the beverage and baking sectors [2]. Future Outlook - The company plans to optimize raw material structure and expand market demand to drive growth in the fuel ethanol segment [2]. - The company is also preparing for the construction of a new starch production facility with an investment of nearly 1 billion, expected to start construction in Q4 of this year [2]. - The allulose product is anticipated to gain traction in the market, with potential for unexpected demand growth if it becomes a popular product [2].